{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:55:48Z","timestamp":1794491748763,"version":"4.9.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T00:00:00Z","timestamp":1621814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T00:00:00Z","timestamp":1621814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2018-02052"],"award-info":[{"award-number":["2018-02052"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2016-00906"],"award-info":[{"award-number":["2016-00906"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003792","name":"Hj\u00e4rnfonden","doi-asserted-by":"publisher","award":["FO2020-0271"],"award-info":[{"award-number":["FO2020-0271"]}],"id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008599","name":"Alzheimerfonden","doi-asserted-by":"publisher","award":["AF-940046"],"award-info":[{"award-number":["AF-940046"]}],"id":[{"id":"10.13039\/501100008599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008599","name":"Alzheimerfonden","doi-asserted-by":"publisher","award":["AF-745911"],"award-info":[{"award-number":["AF-745911"]}],"id":[{"id":"10.13039\/501100008599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"publisher","award":["2017-0383"],"award-info":[{"award-number":["2017-0383"]}],"id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1038\/s41591-021-01348-z","type":"journal-article","created":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T12:03:06Z","timestamp":1621857786000},"page":"1034-1042","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":475,"title":["Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures"],"prefix":"10.1038","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9267-1930","authenticated-orcid":false,"given":"Sebastian","family":"Palmqvist","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pontus","family":"Tideman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Cullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-4354","authenticated-orcid":false,"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1890-4193","authenticated-orcid":false,"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Alzheimer\u2019s Disease Neuroimaging Initiative","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2192-1699","authenticated-orcid":false,"given":"Jeffery L.","family":"Dage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Stomrud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2869-8378","authenticated-orcid":false,"given":"Shorena","family":"Janelidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Mattsson-Carlgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-7286","authenticated-orcid":false,"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,24]]},"reference":[{"key":"1348_CR1","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1001\/jamaneurol.2014.1358","volume":"71","author":"S Palmqvist","year":"2014","unstructured":"Palmqvist, S. et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid \u03b2-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol. 71, 1282\u20131289 (2014).","journal-title":"JAMA Neurol."},{"key":"1348_CR2","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/acn3.274","volume":"3","author":"S Janelidze","year":"2016","unstructured":"Janelidze, S. et al. CSF A\u03b242\/A\u03b240 and A\u03b242\/A\u03b238 ratios: better diagnostic markers of Alzheimer disease. Ann. Clin. Transl. Neurol. 3, 154\u2013165 (2016).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1348_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13195-020-00596-4","volume":"12","author":"NR Barthelemy","year":"2020","unstructured":"Barthelemy, N. R. et al. Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer\u2019s disease and PET amyloid-positive patient identification. Alzheimers Res. Ther. 12, 26 (2020).","journal-title":"Alzheimers Res. Ther."},{"key":"1348_CR4","doi-asserted-by":"publisher","first-page":"eaaz2387","DOI":"10.1126\/sciadv.aaz2387","volume":"6","author":"N Mattsson","year":"2020","unstructured":"Mattsson, N. et al. A\u03b2 deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer\u2019s disease. Sci. Adv. 6, eaaz2387 (2020).","journal-title":"Sci. Adv."},{"key":"1348_CR5","doi-asserted-by":"publisher","first-page":"e2233","DOI":"10.1212\/WNL.0000000000009485","volume":"94","author":"N Mattsson-Carlgren","year":"2020","unstructured":"Mattsson-Carlgren, N. et al. The implications of different approaches to define AT(N) in Alzheimer disease. Neurology 94, e2233\u2013e2244 (2020).","journal-title":"Neurology"},{"key":"1348_CR6","doi-asserted-by":"publisher","unstructured":"Mattsson, N., Palmqvist, S., Stomrud, E., Vogel, J. & Hansson, O. Staging \u03b2-amyloid pathology with amyloid positron emission tomography. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2019.2214 (2019).","DOI":"10.1001\/jamaneurol.2019.2214"},{"key":"1348_CR7","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1001\/jama.2019.2000","volume":"321","author":"GD Rabinovici","year":"2019","unstructured":"Rabinovici, G. D. et al. Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia. JAMA 321, 1286\u20131294 (2019).","journal-title":"JAMA"},{"key":"1348_CR8","doi-asserted-by":"crossref","unstructured":"Leuzy, A. et al. Diagnostic performance of RO948 F 18 tau positron emission tomography in the differentiation of Alzheimer disease from other neurodegenerative disorders. JAMA Neurol. 77, 955\u2013965 (2020).","DOI":"10.1001\/jamaneurol.2020.0989"},{"key":"1348_CR9","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/jama.2018.12917","volume":"320","author":"R Ossenkoppele","year":"2018","unstructured":"Ossenkoppele, R. et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA 320, 1151\u20131162 (2018).","journal-title":"JAMA"},{"key":"1348_CR10","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ebiom.2015.11.036","volume":"3","author":"M Gisslen","year":"2016","unstructured":"Gisslen, M. et al. Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine 3, 135\u2013140 (2016).","journal-title":"EBioMedicine"},{"key":"1348_CR11","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","volume":"25","author":"O Preische","year":"2019","unstructured":"Preische, O. et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer\u2019s disease. Nat. Med. 25, 277\u2013283 (2019).","journal-title":"Nat. Med."},{"key":"1348_CR12","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1001\/jamaneurol.2019.1632","volume":"76","author":"S Palmqvist","year":"2019","unstructured":"Palmqvist, S. et al. Performance of fully automated plasma assays as screening tests for Alzheimer disease-related \u03b2-amyloid status. JAMA Neurol. 76, 1060\u20131069 (2019).","journal-title":"JAMA Neurol."},{"key":"1348_CR13","doi-asserted-by":"publisher","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","volume":"93","author":"SE Schindler","year":"2019","unstructured":"Schindler, S. E. et al. High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology 93, e1647\u2013e1659 (2019).","journal-title":"Neurology"},{"key":"1348_CR14","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze, S. et al. Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat. Med. 26, 379\u2013386 (2020).","journal-title":"Nat. Med."},{"key":"1348_CR15","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari, T. K. et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 19, 422\u2013433 (2020).","journal-title":"Lancet Neurol."},{"key":"1348_CR16","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist, S. et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324, 772\u2013781 (2020).","journal-title":"JAMA"},{"key":"1348_CR17","doi-asserted-by":"crossref","unstructured":"Cullen, N. C. et al. Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. Nat. Aging 1, 114\u2013123 (2021).","DOI":"10.1038\/s43587-020-00003-5"},{"key":"1348_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","volume":"13","author":"CR Jack Jr.","year":"2017","unstructured":"Jack, C. R. Jr. et al. Defining imaging biomarker cut points for brain aging and Alzheimer\u2019s disease. Alzheimers Dement. 13, 205\u2013216 (2017).","journal-title":"Alzheimers Dement."},{"key":"1348_CR19","doi-asserted-by":"publisher","unstructured":"Burnham, K. P. & Anderson, D. R. Multimodel inference: understanding AIC and BIC in model selection. Soc. Methods Res. https:\/\/doi.org\/10.1177\/0049124104268644 (2004).","DOI":"10.1177\/0049124104268644"},{"key":"1348_CR20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.12688\/f1000research.2-71.v1","volume":"2","author":"E Olofsen","year":"2013","unstructured":"Olofsen, E. & Dahan, A. Using Akaike\u2019s information theoretic criterion in mixed-effects modeling of pharmacokinetic data: a simulation study. F1000Research 2, 71 (2013).","journal-title":"F1000Research"},{"key":"1348_CR21","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00401-011-0861-8","volume":"122","author":"JB Toledo","year":"2011","unstructured":"Toledo, J. B. et al. Factors affecting A\u03b2 plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol. 122, 401\u2013413 (2011).","journal-title":"Acta Neuropathol."},{"key":"1348_CR22","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","volume":"13","author":"V Ovod","year":"2017","unstructured":"Ovod, V. et al. Amyloid \u03b2 concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 13, 841\u2013849 (2017).","journal-title":"Alzheimers Dement."},{"key":"1348_CR23","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3233\/JAD-170203","volume":"59","author":"E Borland","year":"2017","unstructured":"Borland, E. et al. The Montreal Cognitive Assessment: normative data from a large Swedish population-based cohort. J. Alzheimers Dis. 59, 893\u2013901 (2017).","journal-title":"J. Alzheimers Dis."},{"key":"1348_CR24","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13195-020-00592-8","volume":"12","author":"E Borland","year":"2020","unstructured":"Borland, E., Stomrud, E., van Westen, D., Hansson, O. & Palmqvist, S. The age-related effect on cognitive performance in cognitively healthy elderly is mainly caused by underlying AD pathology or cerebrovascular lesions: implications for cutoffs regarding cognitive impairment. Alzheimers Res. Ther. 12, 30 (2020).","journal-title":"Alzheimers Res. Ther."},{"key":"1348_CR25","doi-asserted-by":"crossref","unstructured":"Petrazzuoli, F. et al. Brief cognitive tests used in primary care cannot accurately differentiate mild cognitive impairment from subjective cognitive decline. J. Alzheimers Dis. 75, 1191\u20131201 (2020).","DOI":"10.3233\/JAD-191191"},{"key":"1348_CR26","doi-asserted-by":"crossref","unstructured":"Barthelemy, N. R., Horie, K., Sato, C. & Bateman, R. J. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer\u2019s disease. J. Exp. Med. 217, e20200861 (2020).","DOI":"10.1084\/jem.20200861"},{"key":"1348_CR27","doi-asserted-by":"crossref","unstructured":"Karikari, T. K. et al. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer\u2019s Disease Neuroimaging Initiative. Mol. Psychiatry 26, 429\u2013442 (2020).","DOI":"10.1038\/s41380-020-00923-z"},{"key":"1348_CR28","doi-asserted-by":"crossref","unstructured":"Mattsson-Carlgren, N. et al. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer\u2019s disease. Brain 143, 3234\u20133241 (2020).","DOI":"10.1093\/brain\/awaa286"},{"key":"1348_CR29","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","volume":"14","author":"MM Mielke","year":"2018","unstructured":"Mielke, M. M. et al. Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement. 14, 989\u2013997 (2018).","journal-title":"Alzheimers Dement."},{"key":"1348_CR30","doi-asserted-by":"crossref","unstructured":"Palmqvist, S. et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer\u2019s disease. EMBO Mol. Med. 11, e11170 (2019).","DOI":"10.15252\/emmm.201911170"},{"key":"1348_CR31","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1212\/WNL.0000000000007831","volume":"93","author":"PS Insel","year":"2019","unstructured":"Insel, P. S. et al. Determining clinically meaningful decline in preclinical Alzheimer disease. Neurology 93, e322\u2013e333 (2019).","journal-title":"Neurology"},{"key":"1348_CR32","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jalz.2018.08.014","volume":"15","author":"S Palmqvist","year":"2019","unstructured":"Palmqvist, S. et al. Accurate risk estimation of \u03b2-amyloid positivity to identify prodromal Alzheimer\u2019s disease: cross-validation study of practical algorithms. Alzheimers Dement. 15, 194\u2013204 (2019).","journal-title":"Alzheimers Dement."},{"key":"1348_CR33","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.trci.2017.10.004","volume":"3","author":"KV Papp","year":"2017","unstructured":"Papp, K. V., Rentz, D. M., Orlovsky, I., Sperling, R. A. & Mormino, E. C. Optimizing the preclinical Alzheimer\u2019s cognitive composite with semantic processing: the PACC5. Alzheimers Dement. 3, 668\u2013677 (2017).","journal-title":"Alzheimers Dement."},{"key":"1348_CR34","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2015.4668","volume":"313","author":"WJ Jansen","year":"2015","unstructured":"Jansen, W. J. et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 313, 1924\u20131938 (2015).","journal-title":"JAMA"},{"key":"1348_CR35","first-page":"225","volume":"5","author":"O Scheyer","year":"2018","unstructured":"Scheyer, O. et al. Female sex and Alzheimer\u2019s risk: the menopause connection. J. Prev. Alzheimers Dis. 5, 225\u2013230 (2018).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"1348_CR36","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr.","year":"2018","unstructured":"Jack, C. R. Jr. et al. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 14, 535\u2013562 (2018).","journal-title":"Alzheimers Dement."},{"key":"1348_CR37","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","volume":"256","author":"RC Petersen","year":"2004","unstructured":"Petersen, R. C. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 256, 183\u2013194 (2004).","journal-title":"J. Intern. Med."},{"key":"1348_CR38","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1159\/000115751","volume":"30","author":"RO Roberts","year":"2008","unstructured":"Roberts, R. O. et al. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology 30, 58\u201369 (2008).","journal-title":"Neuroepidemiology"},{"key":"1348_CR39","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1159\/000477341","volume":"43","author":"M Gothlin","year":"2017","unstructured":"Gothlin, M., Eckerstrom, M., Rolstad, S., Wallin, A. & Nordlund, A. Prognostic accuracy of mild cognitive impairment subtypes at different cut-off levels. Dement. Geriatr. Cogn. Disord. 43, 330\u2013341 (2017).","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"1348_CR40","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.neuron.2018.02.015","volume":"97","author":"C Sato","year":"2018","unstructured":"Sato, C. et al. Tau kinetics in neurons and the human central nervous system. Neuron 97, 1284\u20131298 (2018).","journal-title":"Neuron"},{"key":"1348_CR41","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1093\/ageing\/afg097","volume":"32","author":"M Lopponen","year":"2003","unstructured":"Lopponen, M., Raiha, I., Isoaho, R., Vahlberg, T. & Kivela, S. L. Diagnosing cognitive impairment and dementia in primary health care\u2014a more active approach is needed. Age Ageing 32, 606\u2013612 (2003).","journal-title":"Age Ageing"},{"key":"1348_CR42","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1001\/archinte.160.19.2964","volume":"160","author":"VG Valcour","year":"2000","unstructured":"Valcour, V. G., Masaki, K. H., Curb, J. D. & Blanchette, P. L. The detection of dementia in the primary care setting. Arch. Intern. Med. 160, 2964\u20132968 (2000).","journal-title":"Arch. Intern. Med."},{"key":"1348_CR43","doi-asserted-by":"crossref","unstructured":"\u00c5strand, R., Rolstad, S. & Wallin, A. Cognitive Impairment Questionnaire (CIMP-QUEST): reported topographic symptoms in MCI and dementia. Acta Neurol. Scand. 121, 384\u2013391 (2009).","DOI":"10.1111\/j.1600-0404.2009.01312.x"},{"key":"1348_CR44","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1093\/geronj\/37.3.323","volume":"37","author":"RI Pfeffer","year":"1982","unstructured":"Pfeffer, R. I., Kurosaki, T. T., Harrah, C. H. Jr., Chance, J. M. & Filos, S. Measurement of functional activities in older adults in the community. J. Gerontol. 37, 323\u2013329 (1982).","journal-title":"J. Gerontol."},{"key":"1348_CR45","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","volume":"141","author":"WG Rosen","year":"1984","unstructured":"Rosen, W. G., Mohs, R. C. & Davis, K. L. A new rating scale for Alzheimer\u2019s disease. Am. J. Psychiatry 141, 1356\u20131364 (1984).","journal-title":"Am. J. Psychiatry"},{"key":"1348_CR46","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/1099-1166(200006)15:6<548::AID-GPS242>3.0.CO;2-U","volume":"15","author":"KI Shulman","year":"2000","unstructured":"Shulman, K. I. Clock-drawing: is it the ideal cognitive screening test? Int J. Geriatr. Psychiatry 15, 548\u2013561 (2000).","journal-title":"Int J. Geriatr. Psychiatry"},{"key":"1348_CR47","doi-asserted-by":"publisher","first-page":"e38639","DOI":"10.1371\/journal.pone.0038639","volume":"7","author":"S Palmqvist","year":"2012","unstructured":"Palmqvist, S. et al. Comparison of brief cognitive tests and CSF biomarkers in predicting Alzheimer\u2019s disease in mild cognitive impairment: six-year follow-up study. PLoS ONE 7, e38639 (2012).","journal-title":"PLoS ONE"},{"key":"1348_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19957-6","volume":"11","author":"N Mattsson-Carlgren","year":"2020","unstructured":"Mattsson-Carlgren, N., Palmqvist, S., Blennow, K. & Hansson, O. Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies. Nat. Commun. 11, 6252 (2020).","journal-title":"Nat. Commun."},{"key":"1348_CR49","doi-asserted-by":"crossref","unstructured":"Hansson, O. et al. CSF biomarkers of Alzheimer\u2019s disease concord with amyloid-\u03b2 PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 14, 1470\u20131481 (2018).","DOI":"10.1016\/j.jalz.2018.01.010"},{"key":"1348_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01150-x","volume":"8","author":"S Palmqvist","year":"2017","unstructured":"Palmqvist, S. et al. Earliest accumulation of \u03b2-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat. Commun. 8, 1214 (2017).","journal-title":"Nat. Commun."},{"key":"1348_CR51","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 7, 263\u2013269 (2011).","journal-title":"Alzheimers Dement."},{"key":"1348_CR52","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.jalz.2015.05.005","volume":"11","author":"PS Aisen","year":"2015","unstructured":"Aisen, P. S., Petersen, R. C., Donohue, M. & Weiner, M. W. & Alzheimer\u2019s Disease Neuroimaging Initiative. Alzheimer\u2019s Disease Neuroimaging Initiative 2 Clinical Core: progress and plans. Alzheimers Dement. 11, 734\u2013739 (2015).","journal-title":"Alzheimers Dement."},{"key":"1348_CR53","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann, G. et al. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology 34, 939\u2013944 (1984).","journal-title":"Neurology"},{"key":"1348_CR54","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/ana.23650","volume":"72","author":"SM Landau","year":"2012","unstructured":"Landau, S. M. et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann. Neurol. 72, 578\u2013586 (2012).","journal-title":"Ann. Neurol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01348-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01348-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01348-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T06:23:06Z","timestamp":1675318986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01348-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,24]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1348"],"URL":"https:\/\/doi.org\/10.1038\/s41591-021-01348-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-134146\/v1","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,24]]},"assertion":[{"value":"22 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.P. has served on the scientific advisory boards for Hoffman-La Roche and Geras Solutions. H.Z. has served on the scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. K.B. has served as a consultant, on advisory boards or on the data monitoring committees for Abcam, Axon, Biogen, JOMDD\/Shimadzu, Julius Clinical, Eli Lilly, MagQu, Novartis, Roche Diagnostics and Siemens Healthineers and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. J.L.D. is an employee of Eli Lilly and Company. O.H. has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, GE Healthcare, Pfizer and Roche. In the past 2 years, O.H. has also received consultancy\/speaker fees from AC Immune, Alzpath, Biogen, Cerveau and Roche. S.J., P.T., N.C., E.S. and N.M.-C. report no disclosures.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}